Erica N Parker

US Patent:

20130296605, Nov 7, 2013

Filed:

Mar 5, 2013

Appl. No.:

13/786142

Inventors:

Erica Parker - Waco TX, US
Kevin G. Pinney - Woodway TX, US
Jiangli Song - Waco TX, US
Mary L. Trawick - Woodway TX, US

International Classification:

C07C 337/08

US Classification:

564 21, 564 20

Abstract:

This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

US Patent:

20210017165, Jan 21, 2021

Filed:

Mar 11, 2019

Appl. No.:

16/980022

Inventors:

- Urbana IL, US
Emily Jane GEDDES - Urbana IL, US
Bryon Shane DROWN - Champaign IL, US
Stephen E. MOTIKA - Urbana IL, US
Erica Nicole PARKER - Urbana IL, US

Assignee:

The Board of Trustees of the University of Illinois - Urbana IL

International Classification:

C07D 409/14

Abstract:

Disclosed herein are antibacterial compounds that accumulate in Gram-negative bacteria, methods of preparing the compounds, and methods of using the compounds to inhibit or kill microbes, and methods of treating microbial infections, such as Gram-negative bacterial infections. Compounds selected for conversion to potential Gram-negative antibacterial compounds were identified based on compounds having low globularity and low flexibility. Amine substituents were then strategically added to the selected compounds to provide compounds having antibacterial activity against Gram-negative bacteria.

US Patent:

20190010173, Jan 10, 2019

Filed:

Aug 12, 2016

Appl. No.:

15/752487

Inventors:

- South San Francisco CA, US
- Waco TX, US
Erica N. Parker - Waco TX, US
David J. Chaplin - San Francisco CA, US

Assignee:

Mateon Therapeutics, Inc. - South San Francisco CA
Baylor University - Waco TX

International Classification:

C07F 9/06
A61K 31/661
A61K 45/06

Abstract:

This present disclosure is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin L, cathepsin K, and/or cathepsin B, will be therapeutically useful. Formula I: or a solvate or pharmaceutically acceptable salt thereof. Each of R1-R10 are independently selected from the group consisting of: hydrogen, alkoxy, halo, hydroxy, phosphate, phosphate salts, disodium phosphate, diphosphate dimer, diphosphate dimer salt, and sodium diphosphate dimer with at least one of R1-R10 is a phosphate or diphosphate dimer group.

US Patent:

20160368869, Dec 22, 2016

Filed:

Aug 31, 2016

Appl. No.:

15/253504

Inventors:

David J. Chaplin - Watlington, GB
Kishore Kumar Gaddale Devanna - Glasgow, GB
Erica Parker - Waco TX, US
Kevin G. Pinney - Woodway TX, US
Jiangli Song - Waco TX, US
Mary Lynn Trawick - Woodway TX, US

International Classification:

C07C 337/08

Abstract:

This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

US Patent:

20150031915, Jan 29, 2015

Filed:

Oct 2, 2014

Appl. No.:

14/505165

Inventors:

- South San Francisco CA, US
- Waco TX, US
Erica Parker - Waco TX, US
Kevin G. Pinney - Woodway TX, US
Jiangli Song - Waco TX, US
Mary L. Trawick - Woodway TX, US

International Classification:

C07C 337/08
C07C 49/786

US Classification:

564 21, 568332, 564 20

Abstract:

This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.